ATE315088T1 - Tumorassoziierte antigenderivate der mage-familie,nukleinsäuresequenzen die dafür kodieren, zur herstellung von fusionsproteinen und zusammensetzungen zur impfung - Google Patents

Tumorassoziierte antigenderivate der mage-familie,nukleinsäuresequenzen die dafür kodieren, zur herstellung von fusionsproteinen und zusammensetzungen zur impfung

Info

Publication number
ATE315088T1
ATE315088T1 AT99907476T AT99907476T ATE315088T1 AT E315088 T1 ATE315088 T1 AT E315088T1 AT 99907476 T AT99907476 T AT 99907476T AT 99907476 T AT99907476 T AT 99907476T AT E315088 T1 ATE315088 T1 AT E315088T1
Authority
AT
Austria
Prior art keywords
vaccination
tumor
compositions
code
nucleic acid
Prior art date
Application number
AT99907476T
Other languages
English (en)
Inventor
Silva Teresa Cabezon
Joseph Cohen
Moncef Slaoui
Bassols Carlota Vinals
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9802543.0A external-priority patent/GB9802543D0/en
Priority claimed from GBGB9802650.3A external-priority patent/GB9802650D0/en
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Application granted granted Critical
Publication of ATE315088T1 publication Critical patent/ATE315088T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001186—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/285—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pasteurellaceae (F), e.g. Haemophilus influenza
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C07K14/3156—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci from Streptococcus pneumoniae (Pneumococcus)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
AT99907476T 1998-02-05 1999-02-02 Tumorassoziierte antigenderivate der mage-familie,nukleinsäuresequenzen die dafür kodieren, zur herstellung von fusionsproteinen und zusammensetzungen zur impfung ATE315088T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9802543.0A GB9802543D0 (en) 1998-02-05 1998-02-05 Vaccine
GBGB9802650.3A GB9802650D0 (en) 1998-02-06 1998-02-06 Vaccine

Publications (1)

Publication Number Publication Date
ATE315088T1 true ATE315088T1 (de) 2006-02-15

Family

ID=26313069

Family Applications (4)

Application Number Title Priority Date Filing Date
AT06075363T ATE513042T1 (de) 1998-02-05 1999-02-02 Tumorassoziierte antigenderivate der mage-familie,nukleinsäuresequenzen, die dafür kodieren, zur herstellung von fusionsproteinen und zusammensetzungen zur impfung
AT99907476T ATE315088T1 (de) 1998-02-05 1999-02-02 Tumorassoziierte antigenderivate der mage-familie,nukleinsäuresequenzen die dafür kodieren, zur herstellung von fusionsproteinen und zusammensetzungen zur impfung
AT06075362T ATE462788T1 (de) 1998-02-05 1999-02-02 Verfahren zur reinigung oder herstellung der mage protein
AT05076599T ATE505542T1 (de) 1998-02-05 1999-02-02 Tumorassoziierte antigenderivate der mage-familie,zur herstellung von fusionsproteinen mit t-helper epitope und zusammensetzungen zur impfung

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT06075363T ATE513042T1 (de) 1998-02-05 1999-02-02 Tumorassoziierte antigenderivate der mage-familie,nukleinsäuresequenzen, die dafür kodieren, zur herstellung von fusionsproteinen und zusammensetzungen zur impfung

Family Applications After (2)

Application Number Title Priority Date Filing Date
AT06075362T ATE462788T1 (de) 1998-02-05 1999-02-02 Verfahren zur reinigung oder herstellung der mage protein
AT05076599T ATE505542T1 (de) 1998-02-05 1999-02-02 Tumorassoziierte antigenderivate der mage-familie,zur herstellung von fusionsproteinen mit t-helper epitope und zusammensetzungen zur impfung

Country Status (25)

Country Link
US (3) US8097257B2 (de)
EP (4) EP1584685B1 (de)
JP (2) JP4768121B2 (de)
KR (2) KR100633212B1 (de)
CN (1) CN1227360C (de)
AR (1) AR018064A1 (de)
AT (4) ATE513042T1 (de)
AU (1) AU737337B2 (de)
BR (1) BR9907691B1 (de)
CA (2) CA2319309C (de)
CY (4) CY1105685T1 (de)
CZ (2) CZ298347B6 (de)
DE (3) DE69942214D1 (de)
DK (4) DK1053325T3 (de)
ES (2) ES2255248T3 (de)
HU (1) HU228467B1 (de)
IL (4) IL137442A0 (de)
NO (2) NO328507B1 (de)
NZ (1) NZ506086A (de)
PT (4) PT1659178E (de)
SA (1) SA99200126B1 (de)
SI (4) SI1659179T1 (de)
TR (1) TR200002284T2 (de)
TW (1) TWI238853B (de)
WO (1) WO1999040188A2 (de)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE513042T1 (de) 1998-02-05 2011-07-15 Glaxosmithkline Biolog Sa Tumorassoziierte antigenderivate der mage-familie,nukleinsäuresequenzen, die dafür kodieren, zur herstellung von fusionsproteinen und zusammensetzungen zur impfung
SI1117421T1 (en) * 1998-10-05 2004-12-31 Pharamexa A/S Methods for therapeutic vaccination
CA2345817C (en) 1998-10-05 2013-02-12 M&E Biotech A/S Novel methods for therapeutic vaccination
GB9908885D0 (en) * 1999-04-19 1999-06-16 Smithkline Beecham Biolog Vccine
CN1254541C (zh) 2000-02-23 2006-05-03 史密丝克莱恩比彻姆生物有限公司 新化合物
ATE398463T1 (de) * 2000-04-13 2008-07-15 Corixa Corp Immunostimulierende zusammnensetzungen die aminoalkyl glucosaminidephosphat und qs-21 enthalten
ATE346925T1 (de) * 2000-05-10 2006-12-15 Sanofi Pasteur Ltd Durch mage minigene kodierte immunogene polypeptide und ihre verwendungen
AUPQ761200A0 (en) * 2000-05-19 2000-06-15 Hunter Immunology Limited Compositions and methods for treatment of mucosal infections
EP1290028B1 (de) * 2000-06-05 2009-12-23 The Brigham And Women's Hospital, Inc. Für ein homologes des humanen, für mehrfachresistenz verantwortlichen, p-glykoproteins auf chromosom 7p15-21 kodierendes gen sowie verwendungen dafür
DE60139963D1 (de) 2000-06-20 2009-10-29 Corixa Corp Fusionsproteine aus mycobakterium tuberculosis
DK1889630T3 (da) * 2000-10-18 2012-03-05 Glaxosmithkline Biolog Sa Vacciner omfattende MAGE-antigen koblet til protein D-fragment
HU229642B1 (en) * 2000-10-18 2014-03-28 Glaxosmithkline Beecham Biolog S A Vaccines against cancers
GB0109297D0 (en) 2001-04-12 2001-05-30 Glaxosmithkline Biolog Sa Vaccine
AU2002364161A1 (en) 2001-12-12 2003-06-23 Aventis Pasteur Limited Enhancement of the immune response using cd36-binding domain
DE602004031681D1 (de) 2003-07-21 2011-04-14 Transgene Sa Multifunktionelle Cytokine
EP1660526A1 (de) * 2003-08-29 2006-05-31 The Nottingham Trent University Antigene, die mit magen- und prostatakrebs im zusammenhang stehen
EP1670509A4 (de) * 2003-09-03 2007-10-31 Dendritherapeutics Inc Multiplex-vakzine
GB0321615D0 (en) 2003-09-15 2003-10-15 Glaxo Group Ltd Improvements in vaccination
GB0409940D0 (en) * 2004-05-04 2004-06-09 Glaxosmithkline Biolog Sa Vaccine
BRPI0609547A2 (pt) 2005-03-31 2011-10-18 Glaxosmithkline Biolog Sa composição, uso de uma composição, método para o tratamento ou prevenção de infecção por chlamydia, uso de uma ou mais proteìnas de chlamydia, de fragmentos imunogênicos das mesmas ou de polinucleotìdeos codificando os mesmos, método para o tratamento ou prevenção de infecção por chlamydia, e, método para a determinação prévia de infecção por chlamydia em um indivìduo
SI2457926T1 (sl) 2005-04-29 2015-01-30 Glaxosmithkline Biologicals S.A. Nov postopek za preprečevanje ali zdravljenje infekcije z M. tuberculosis
ATE515566T1 (de) * 2005-05-26 2011-07-15 Cytos Biotechnology Ag Skalierbares fermentationsverfahren
US7700567B2 (en) 2005-09-29 2010-04-20 Supergen, Inc. Oligonucleotide analogues incorporating 5-aza-cytosine therein
CA2630023A1 (en) * 2005-11-14 2007-05-18 Universite Laval Cancer antigen mage-a9 and uses thereof
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
JP5170976B2 (ja) * 2006-04-11 2013-03-27 株式会社イミュノフロンティア タンパク質複合体およびその製造方法
TW200817680A (en) 2006-06-02 2008-04-16 Glaxosmithkline Biolog Sa Method
GB0612342D0 (en) * 2006-06-21 2006-08-02 Glaxosmithkline Biolog Sa Method
KR101378872B1 (ko) 2006-09-26 2014-04-11 인펙셔스 디지즈 리서치 인스티튜트 (아이디알아이) 합성 애주번트를 함유하는 백신 조성물
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
GB0700284D0 (en) * 2007-01-08 2007-02-14 Glaxosmithkline Biolog Sa Combination therapy
KR20090101313A (ko) 2007-01-15 2009-09-24 글락소스미스클라인 바이오로지칼즈 에스.에이. 백신
KR20100061477A (ko) * 2007-09-11 2010-06-07 몬도바이오테크 래보래토리즈 아게 치료제로서의 펩티드 ａｓｎ-ａｓｐ-ａｓｐ-ｃｙｓ-ｇｌｕ-ｌｅｕ-ｃｙｓ-ｖａｌ-ａｓｎ-ｖａｌ-ａｌａ-ｃｙｓ-ｔｈｒ-ｇｌｙ-ｃｙｓ-ｌｅｕ-ｏｈ 단독 또는 펩티드 ｔｈｒ-ｔｈｒ-ｓｅｒ-ｇｌｎ-ｖａｌ-ａｒｇ-ｐｒｏ-ａｒｇ-ｏｈ와의 배합물의 용도
WO2009033680A2 (en) * 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Galanin-like peptide alone or in combination with cyclo-argd as a therapeutic agent
CA2699856C (en) * 2007-09-17 2019-08-20 Oncomethylome Sciences Sa Improved methylation detection
BR122016015627A2 (pt) * 2007-10-19 2018-10-30 Novartis Ag kit, composição antigênica liofilizada e método para preparação de uma composição imunogênica
EP2408933A2 (de) 2009-03-17 2012-01-25 MDxHealth SA Verbesserter genexpressionsnachweis
NZ596501A (en) 2009-05-27 2013-11-29 Glaxosmithkline Biolog Sa Casb7439 constructs
SI2437753T1 (sl) 2009-06-05 2016-12-30 Infectious Disease Research Institute Sintetični glukopiranozil-lipidni adjuvansi in cepivni sestavki, ki jih vsebujejo
GB0910046D0 (en) 2009-06-10 2009-07-22 Glaxosmithkline Biolog Sa Novel compositions
GB0917457D0 (en) 2009-10-06 2009-11-18 Glaxosmithkline Biolog Sa Method
UA110103C2 (uk) 2010-01-27 2015-11-25 Ґлаксосмітклайн Байолоджікалз С.А. Модифікований туберкульозний антиген
GB201022007D0 (en) 2010-12-24 2011-02-02 Imp Innovations Ltd DNA-sensor
US20120263754A1 (en) 2011-02-15 2012-10-18 Immune Design Corp. Methods for Enhancing Immunogen Specific Immune Responses by Vectored Vaccines
BRPI1100857A2 (pt) * 2011-03-18 2013-05-21 Eduardo Nowill Alexandre agente imunomodulador e suas combinaÇÕes, seu uso e mÉtodo imunoterÁpico para a recontextualizaÇço, reprogramaÇço e reconduÇço do sistema imune em tempo real
AU2012243039B2 (en) 2011-04-08 2017-07-13 Immune Design Corp. Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
CN102251034B (zh) * 2011-07-05 2012-11-21 北京大学人民医院 基于mage-c2/ct10基因辅助诊断多发性骨髓瘤患者的定量检测试剂盒
PH12018501678B1 (en) 2011-08-30 2022-08-10 Astex Pharmaceuticals Inc Decitabine derivative formulations
GB201116248D0 (en) 2011-09-20 2011-11-02 Glaxosmithkline Biolog Sa Liposome production using isopropanol
KR20140107576A (ko) * 2011-12-22 2014-09-04 글락소스미스클라인 엘엘씨 Braf 저해제 및/또는 mek 저해제와 magea3 면역치료제를 이용한 암 치료 방법
CN110339160A (zh) 2012-02-07 2019-10-18 传染性疾病研究院 包含tlr4激动剂的改进佐剂制剂及其使用方法
PT2850431T (pt) 2012-05-16 2018-07-23 Immune Design Corp Vacinas para hsv-2
EP3587455A1 (de) 2012-10-23 2020-01-01 Emory University Gm-csf- und il-4-konjugate, zusammensetzungen und zugehörige verfahren
MX366967B (es) 2013-03-01 2019-07-31 Astex Pharmaceuticals Inc Combinaciones de farmacos.
EP3711768A1 (de) 2013-04-18 2020-09-23 Immune Design Corp. Gla-monotherapie zur verwendung in der krebsbehandlung
US9849066B2 (en) 2013-04-24 2017-12-26 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
WO2015092710A1 (en) 2013-12-19 2015-06-25 Glaxosmithkline Biologicals, S.A. Contralateral co-administration of vaccines
IL310015B2 (en) 2013-12-31 2026-02-01 Access To Advanced Health Inst Single vial formulation
WO2015123496A1 (en) 2014-02-14 2015-08-20 Immune Design Corp. Immunotherapy of cancer through combination of local and systemic immune stimulation
KR20170032373A (ko) 2014-07-15 2017-03-22 이뮨 디자인 코포레이션 Tlr4 작용제 보조제 및 렌티바이러스 벡터를 이용한 프라임-부스트 요법
EP3316685A4 (de) 2015-07-02 2019-03-13 Otsuka Pharmaceutical Co., Ltd. Lyophilisierte pharmazeutische zusammensetzungen
CN105181966B (zh) * 2015-09-02 2017-08-11 南通大学附属医院 一种mage‑a9的用途
KR102566134B1 (ko) 2015-12-07 2023-08-10 삼성전자주식회사 반도체 소자의 3d 프로파일링 시스템 및 이의 동작 방법
WO2017176076A1 (en) 2016-04-06 2017-10-12 Ewha University - Industry Collaboration Foundation A peptide with ability to penetrate cell membrane
EP3443123B1 (de) 2016-04-11 2021-08-11 Board of Regents, The University of Texas System Verfahren und zusammensetzungen zum nachweis der affinität einzelner t-zellrezeptoren und sequenz
EP4112638A1 (de) 2016-05-16 2023-01-04 Access to Advanced Health Institute Formulierung mit tlr-agonist und verfahren zur verwendung
IL263030B2 (en) 2016-05-16 2024-11-01 Access To Advanced Health Inst Pegylated liposomes and methods of use
KR102748354B1 (ko) 2016-06-01 2024-12-31 액세스 투 어드밴스드 헬스 인스티튜트 사이징제를 함유하는 나노명반 입자
KR102673794B1 (ko) 2017-06-15 2024-06-11 액세스 투 어드밴스드 헬스 인스티튜트 나노구조 지질 담체 및 안정적인 에멀션 그리고 이들의 용도
EP3661522A2 (de) 2017-08-03 2020-06-10 Otsuka Pharmaceutical Co., Ltd. Arzneimittelverbindung und reinigungsverfahren dafür
CN111315406A (zh) 2017-09-08 2020-06-19 传染病研究所 包括皂苷的脂质体调配物及其使用方法
SG11202010262TA (en) 2018-04-19 2020-11-27 Baylor College Medicine Reprogramming cd4 t cells into cytotoxic cd8 cells by forced expression of cd8ab and class 1 restricted t cell receptors
US20220033848A1 (en) 2018-11-19 2022-02-03 Board Of Regents, The University Of Texas System A modular, polycistronic vector for car and tcr transduction
AU2019386140A1 (en) 2018-11-28 2021-06-24 Board Of Regents, The University Of Texas System Multiplex genome editing of immune cells to enhance functionality and resistance to suppressive environment
WO2020112493A1 (en) 2018-11-29 2020-06-04 Board Of Regents, The University Of Texas System Methods for ex vivo expansion of natural killer cells and use thereof
BR112021023726A2 (pt) 2019-05-25 2022-02-15 Infectious Disease Res Inst Composição e método para secagem por pulverização de uma emulsão de vacina adjuvante
US20230106973A1 (en) 2020-02-17 2023-04-06 Board Of Regents, The University Of Texas System Methods for expansion of tumor infiltrating lymphocytes and use thereof
CA3179694A1 (en) * 2020-04-17 2021-10-21 The Francis Crick Institute Limited Fusion proteins of ctl antigens for treating melanoma
CA3173951A1 (en) 2020-09-04 2022-03-10 Emily VOIGT Genetically-adjuvanted rna vaccines
CA3174411A1 (en) 2020-09-04 2022-03-10 Ryan M. Kramer Co-lyophilized rna and nanostructured lipid carrier
EP4243839A1 (de) 2020-11-13 2023-09-20 Catamaran Bio, Inc. Genetisch modifizierte natürliche killerzellen und verfahren zur verwendung davon
AU2021388155A1 (en) 2020-11-25 2023-06-15 Catamaran Bio, Inc. Cellular therapeutics engineered with signal modulators and methods of use thereof
CA3173408A1 (en) 2020-12-23 2022-06-30 Access To Advanced Health Institute Solanesol vaccine adjuvants and methods of preparing same
CA3217028A1 (en) 2021-04-22 2022-10-27 Baylor College Of Medicine Methods of engineering immune cells having reduced fratricidal activity
EP4169513A1 (de) 2021-10-19 2023-04-26 GlaxoSmithKline Biologicals S.A. Hilfsstoffzusammensetzung enthaltend sting agonisten
WO2023089556A1 (en) 2021-11-22 2023-05-25 Pfizer Inc. Reducing risk of antigen mimicry in immunogenic medicaments
WO2023211972A1 (en) 2022-04-28 2023-11-02 Medical University Of South Carolina Chimeric antigen receptor modified regulatory t cells for treating cancer
EP4583841A1 (de) 2022-09-09 2025-07-16 Access to Advanced Health Institute Immunogene impfstoffzusammensetzung mit einem saponin

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4302386A (en) 1978-08-25 1981-11-24 The Ohio State University Antigenic modification of polypeptides
US4526716A (en) 1981-11-20 1985-07-02 The Ohio State University Antigenic modification of polypeptides
US4384995A (en) 1980-01-16 1983-05-24 The Ohio State University Antigenic modification of polypeptides
US5833975A (en) 1989-03-08 1998-11-10 Virogenetics Corporation Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence
AR241713A1 (es) 1984-08-30 1992-11-30 Smithkline Beckman Corp Molecula de dna con una secuencia de bases que codifica la proteina c13 y preparacion de vacunas contra la gripe.
ZA896627B (en) * 1988-08-31 1991-03-27 Smithkline Beecham Corp Vaccinal polypeptides
GB8824496D0 (en) 1988-10-19 1988-11-23 Beecham Group Plc Process
US6780407B1 (en) 1989-03-08 2004-08-24 Aventis Pasteur Pox virus comprising DNA sequences encoding CEA and B7 antigen
CA2022752C (en) 1989-08-11 1998-07-07 Naomi Kitamura Hepatic parenchymal cell growth factor, gene encoding the same, process for producing the factor, and transformants producing the factor
GB8927546D0 (en) * 1989-12-06 1990-02-07 Ciba Geigy Process for the production of biologically active tgf-beta
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
AU8294991A (en) 1990-07-23 1992-02-18 Zymogenetics Inc. Protease resistant pdgf and methods of use
US5925729A (en) 1991-05-23 1999-07-20 Ludwig Institute For Cancer Research Tumor rejection antigen precursors, tumor rejection antigens and uses thereof
US6235525B1 (en) 1991-05-23 2001-05-22 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for tumor rejection antigen precursor MAGE-3 and uses thereof
US5541104A (en) 1991-05-23 1996-07-30 Ludwig Institute For Cancer Research Monoclonal antibodies which bind to tumor rejection antigen precursor mage-1
US5342774A (en) 1991-05-23 1994-08-30 Ludwig Institute For Cancer Research Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1
DK0676964T3 (da) 1991-11-14 2001-02-05 Brigham & Womens Hospital Nitrosylering af enzym-SH-grupper som en terapeutisk modalitet
GB9213559D0 (en) 1992-06-25 1992-08-12 Smithkline Beecham Biolog Vaccines
CA2138997C (en) 1992-06-25 2003-06-03 Jean-Paul Prieels Vaccine composition containing adjuvants
AU668772B2 (en) 1992-08-31 1996-05-16 Ludwig Institute For Cancer Research Isolated nonapeptide derived from mage-3 gene and presented by HLA-A1, and uses thereof
JPH09502086A (ja) * 1993-08-06 1997-03-04 サイテル コーポレイション 完全ｍａｇｅ１遺伝子のクローニング及び特性決定
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
NZ282536A (en) 1994-03-01 1998-07-28 Ludwig Inst Cancer Res Nucleic acid molecule useful as a primer in determining expression of a mage tumour rejections antigen precursor
US5879687A (en) * 1994-04-22 1999-03-09 Corixa Corporation Methods for enhancement of protective immune responses
WO1996002555A1 (en) 1994-07-15 1996-02-01 The University Of Iowa Research Foundation Immunomodulatory oligonucleotides
WO1996010413A1 (en) * 1994-09-30 1996-04-11 Ludwig Institute For Cancer Research Compositions containing tumor rejection antigen precursors or tumor rejection antigens, and an adjuvant and/or growth factor
US5612030A (en) * 1995-01-17 1997-03-18 University Of Kentucky Research Foundation Anti-idiotype monoclonal antibody 1A7 and use for the treatment of melanoma and small cell carcinoma
US6017705A (en) 1995-03-14 2000-01-25 Ludwig Institute For Cancer Research Isolated nucleic acid molecules which are members of the MAGE-B family and uses thereof
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
EP0873350A4 (de) 1995-06-29 1999-06-30 Ludwig Inst Cancer Res Isolierte nukleinsäuremoleküle, die den maustumoralstossungs-antigenvorläufer smage-3 kodieren
WO1997013858A2 (en) 1995-10-12 1997-04-17 Chiron Corporation Baboon mage-3 homologs, dna encoding the homologs, and a process for their use
US6265215B1 (en) 1996-09-13 2001-07-24 Ludwig Institute For Cancer Research Isolated peptides which complex with HLA-Cw16 and uses thereof
US5908778A (en) 1996-10-03 1999-06-01 Ludwig Institute For Cancer Research Mage-10 encoding cDNA, the tumor rejection antigen precursor mage-10, antibodies specific to the molecule, and uses thereof
CA2218456A1 (en) 1996-10-15 1998-04-15 The Rockefeller University Purified stat proteins and methods of purifying thereof
EP0941366A2 (de) 1996-11-06 1999-09-15 Whitehead Institute For Biomedical Research Biallelische marker
US7157089B1 (en) 1996-11-26 2007-01-02 Stressgen Biotechnologies Corporation Immune responses using compositions containing stress proteins
US6340461B1 (en) 1996-12-17 2002-01-22 David Stephen Terman Superantigen based methods and compositions for treatment of diseases
US6287569B1 (en) 1997-04-10 2001-09-11 The Regents Of The University Of California Vaccines with enhanced intracellular processing
US6680191B1 (en) 1997-04-25 2004-01-20 Ludwig Institute For Cancer Isolated nucleic acid molecules coding for tumor rejection antigen precursors of members of the MAGE-C and MAGE-B FAMILIES and uses thereof
US6027924A (en) 1997-04-25 2000-02-22 Ludwig Institute For Cancer Research Isolated nucleic acid molecule coding for tumor rejection antigen precursor MAGE-C1 and uses thereof
US20020176865A1 (en) 1997-04-25 2002-11-28 Sophie Lucas Isolated nucleic acid molecules coding for tumor rejection antigen precursors of members of the MAGE-C and MAGE-B families and uses thereof
US6043084A (en) 1997-10-10 2000-03-28 Ludwig Institute For Cancer Research Isolated nucleic acid molecules associated with colon cancer and methods for diagnosing and treating colon cancer
US5965535A (en) 1997-09-12 1999-10-12 Ludwig Institute For Cancer Research Mage-3 peptides presented by HLA class II molecules
US6716809B1 (en) 1997-09-12 2004-04-06 Ludwig Institute For Cancer Research Mage-A3 peptides presented by HLA class molecules
US6291430B1 (en) 1997-09-12 2001-09-18 Ludwig Institute For Cancer Research Mage-3 peptides presented by HLA class II molecules
ATE513042T1 (de) 1998-02-05 2011-07-15 Glaxosmithkline Biolog Sa Tumorassoziierte antigenderivate der mage-familie,nukleinsäuresequenzen, die dafür kodieren, zur herstellung von fusionsproteinen und zusammensetzungen zur impfung
AU3371199A (en) 1998-04-09 1999-11-01 Whitehead Institute For Biomedical Research Biallelic markers
US6686147B1 (en) 1998-07-15 2004-02-03 Ludwig Institute For Cancer Research Cancer associated antigens and uses therefor

Also Published As

Publication number Publication date
DK1659179T3 (da) 2011-10-10
KR20010040675A (ko) 2001-05-15
SI1053325T1 (sl) 2006-06-30
IL188875A (en) 2011-08-31
ATE513042T1 (de) 2011-07-15
HUP0102639A3 (en) 2004-04-28
DE69929310T2 (de) 2006-08-03
SI1659178T1 (sl) 2010-07-30
JP4768121B2 (ja) 2011-09-07
KR20060067977A (ko) 2006-06-20
HUP0102639A1 (hu) 2001-11-28
DE69942214D1 (de) 2010-05-12
US20120269835A1 (en) 2012-10-25
JP2009201510A (ja) 2009-09-10
CN1295616A (zh) 2001-05-16
CA2584482A1 (en) 1999-08-12
IL137442A0 (en) 2001-07-24
IL179010A0 (en) 2007-03-08
EP1659179A2 (de) 2006-05-24
DK1053325T3 (da) 2006-05-22
HK1093522A1 (en) 2007-03-02
US8044183B2 (en) 2011-10-25
NO20003958L (no) 2000-10-04
HU228467B1 (en) 2013-03-28
EP1584685A3 (de) 2005-12-07
CZ298364B6 (cs) 2007-09-05
HK1093521A1 (en) 2007-03-02
EP1053325B1 (de) 2006-01-04
NZ506086A (en) 2003-01-31
CY1105685T1 (el) 2010-12-22
KR100824105B1 (ko) 2008-04-21
EP1659178A3 (de) 2007-01-17
WO1999040188A3 (en) 1999-10-14
PT1659179E (pt) 2011-09-16
EP1659178B1 (de) 2010-03-31
EP1659178A2 (de) 2006-05-24
NO328507B1 (no) 2010-03-08
CA2319309C (en) 2010-08-10
NO331719B1 (no) 2012-03-05
CZ298347B6 (cs) 2007-09-05
HK1033838A1 (en) 2001-09-28
EP1659179A3 (de) 2007-01-17
KR100633212B1 (ko) 2006-10-11
US20100204458A1 (en) 2010-08-12
AU737337B2 (en) 2001-08-16
DK1584685T3 (da) 2011-07-11
PT1659178E (pt) 2010-06-28
CY1110180T1 (el) 2015-01-14
CY1111672T1 (el) 2015-10-07
EP1659179B1 (de) 2011-06-15
IL137442A (en) 2008-04-13
BR9907691B1 (pt) 2011-05-31
EP1053325A2 (de) 2000-11-22
AU2722099A (en) 1999-08-23
DE69929310D1 (de) 2006-03-30
JP2002502604A (ja) 2002-01-29
EP1584685A2 (de) 2005-10-12
HK1083026A1 (en) 2006-06-23
PT1053325E (pt) 2006-05-31
CN1227360C (zh) 2005-11-16
SI1659179T1 (sl) 2011-10-28
US8597656B2 (en) 2013-12-03
CZ20002869A3 (cs) 2001-01-17
PL342852A1 (en) 2001-07-16
DE69943359D1 (de) 2011-05-26
CY1111831T1 (el) 2015-10-07
ATE462788T1 (de) 2010-04-15
EP1584685B1 (de) 2011-04-13
ES2255248T3 (es) 2006-06-16
TWI238853B (en) 2005-09-01
SA99200126B1 (ar) 2006-08-20
US20100209444A1 (en) 2010-08-19
US8097257B2 (en) 2012-01-17
WO1999040188A2 (en) 1999-08-12
AR018064A1 (es) 2001-10-31
NO20003958D0 (no) 2000-08-04
IL188875A0 (en) 2009-02-11
CA2584482C (en) 2012-03-27
DK1659178T3 (da) 2010-07-12
TR200002284T2 (tr) 2000-11-21
PT1584685E (pt) 2011-06-17
BR9907691A (pt) 2000-11-14
NO20091665L (no) 2000-10-04
ES2342416T3 (es) 2010-07-06
ATE505542T1 (de) 2011-04-15
CA2319309A1 (en) 1999-08-12
SI1584685T1 (sl) 2011-07-29

Similar Documents

Publication Publication Date Title
DE69929310D1 (de) Tumorassoziierte antigenderivate der mage-familie, nukleinsäuresequenzen die dafür kodieren, zur herstellung von fusionsproteinen und zusammensetzungen zur impfung
DE50303749D1 (de) Verfahren zur herstellung von phthalocyaninpigmentzubereitungen
EP1576108A4 (de) Nitrilasen, diese codierende nukleinsäuren sowie verfahren zur herstellung und verwendung davon
DE60223070D1 (de) Verfahren zur herstellung von dihalogenadamantanen
DE60219193D1 (de) Verfahren zur herstellung von silylorganomercaptanen
DE60208738D1 (de) Verfahren zur Herstellung von Chlorfluorpolyoxyalkylenolen
WO2001032882A3 (en) Nucleic acids and proteins from group b streptococcus
DE60239842D1 (de) Verfahren zur Herstellung von 10,11-dihydro-10-oxo-5h-dibenzoÄb,fÜazepin-5-carboxamid
DE60200099D1 (de) Verfahren zur Herstellung von Isobutylenpolymeren
DE50210487D1 (de) Verfahren zur Herstellung von 1-Amino-4-hydroxyanthrachinonen
DE60222806D1 (de) Verfahren zur herstellung von (1,4,5)-oxadiazepinderivaten
DE60218586D1 (de) Verfahren zur Herstellung von Liganden-Arrays
DE60209171D1 (de) Verfahren zur Herstellung von Bromfluorenen
DE69936449D1 (de) Verfahren zur herstellung von 1,3-disubstituierten-4-oxocyclischen harnstoffen
DE60228444D1 (de) Verfahren zur herstellung von cumylphenol
DE60108105D1 (de) Verfahren zur Herstellung von 5-substituierten Isobenzofuranen
DE59802620D1 (de) Verfahren zur Herstellung von trans-(R,R)-Actinol
DE50207073D1 (de) Verfahren zur Herstellung von Acyloxybenzolsulfonaten
DE60032308T8 (de) Verfahren zur Herstellung von Trichloressigsäure
DE69920003D1 (de) Verfahren zur herstellung von 1,3-disubstituierten-4-oxocyclischen harnstoffen
DE60104789D1 (de) Verfahren zur Herstellung von 2,4,5-Trialkylbenzaldehyden
DE69801454D1 (de) Verfahren zur Herstellung von 2-Methyl-1,4-Benzochinon
DE60230097D1 (de) Verfahren zur herstellung von 1,5-diaminonaphthalinen
DE50203573D1 (de) Einstufiges verfahren zur herstellung von trimethoxytoluol
DE60143350D1 (de) Verfahren zur herstellung von 1,3-dialkyl-2-imidazolidinon-derivaten

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1053325

Country of ref document: EP